Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Overview
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
EstryX Pharma Ltd
Kalgene Pharmaceuticals Inc
SiglChem Lifesciences Corp
Telix Pharmaceuticals Ltd
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drug Profiles
(acetazolamide + temozolomide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESE-15-ol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CA9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TX-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CA9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Dormant Products
Carbonic Anhydrase 9 (Carbote Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Rel Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Product Development Milestones
Featured News & Press Releases
Aug 30, 2019: Telix Pharmaceuticals to launch Japanese Rel Cancer Imaging Study
Aug 20, 2019: First Australian patient dosed in ZIRCON phase III trial
Jul 19, 2019: Telix Pharmaceuticals: Japanese regulatory update for rel cancer imaging program
Jul 15, 2019: Telix Pharmaceuticals reports positive phase III meeting with the FDA
Jun 13, 2019: Telix Pharmaceuticals and Eczacibasi-Monrol sign manufacturing and distribution agreement
Jun 05, 2019: Heidelberg Pharma receives milestone payment from partner Telix
Mar 20, 2019: cGMP manufacturing of TLX250 complete
Oct 23, 2018: Telix commences ZIRCON phase III rel cancer imaging trial
Oct 17, 2018: Telix Selects RTM to Manufacture Kidney Imaging Program in Europe
Oct 15, 2018: Interim alysis of 89 Zr-TLX250-CDx bridging study (“ZIR - DOSE”) demonstrates significantly improved patient dosimetry
Oct 15, 2018: Telix and Cyclotek Enter into Manufacturing Partnership for Kidney Cancer Imaging
Aug 23, 2018: Heidelberg Pharma: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Jul 26, 2018: Telix Pharmaceuticals and JFE Progress japanese manufacturing partnership
Jun 25, 2018: Telix and Isologic conclude manufacturing agreement for North America
May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up Partner
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Akshaya Bio Inc, H2 2019
Pipeline by EstryX Pharma Ltd, H2 2019
Pipeline by Kalgene Pharmaceuticals Inc, H2 2019
Pipeline by SignalChem Lifesciences Corp, H2 2019
Pipeline by Telix Pharmaceuticals Ltd, H2 2019
Dormant Projects, H2 2019